Aspect has acquired rights to Novo Nordisk’s stem cell-derived islet cell and hypoimmune cell engineering technologies
The clearance marks a major step in Diabeloop’s ambition to become a central partner for insulin pump manufacturers and expand access to automated insulin delivery in the US market
Qfitlia is the first antithrombin (AT)-lowering therapy approved for routine prophylaxis in hemophilia
The company's net income attributable to equity holders dropped to €2.80 billion from €2.82 billion last year
Now integrates with Abbott’s instinct sensor and approved for type 2 diabetes
The huminsulin range of products is indicated for the treatment of type 1 and type 2 diabetes mellitus to improve blood sugar control in both adults and childre
Good momentum in commercial CDMO business
Dr. Jain is a biotechnology industry veteran with more than two decades of experience in pharmaceutical development across her time with ChemoCentryx, AbbVie, Abbott Laboratories, and G.D. Searle and Co
He has published more than 100 research papers in several prestigious national and international journals
Subscribe To Our Newsletter & Stay Updated
